Thursday, 10 May 2018

Appendicitis Market Analysis, Study and Pipeline Review 2018

Market Synopsis of the Global Appendicitis Market
Inflammation of the appendix is known as appendicitis. Abdominal pain, loss of appetite, nausea and vomiting, fever, and abdominal tenderness are common symptoms of appendicitis. The condition can be diagnosed by imaging test such as abdominal X-ray, ultrasonography, CT scan, and laparoscopy. CT scan is found to be more accurate than ultrasound examination for detecting acute appendicitis. If the condition is untreated, it many lead to perforation of the appendix, and infectious fluids many spill into the abdominal cavity. This can lead to peritonitis, an inflammation of the abdominal cavity's lining which may be fatal. 
Rising demand for diagnostic and treatment options of appendicitis, and increasing prevalence of appendicitis are the major driver for the growth of appendicitis market across the globe. The market is also accelerated due to the growth of medical device industry in developed regions. The U.S. product differentiation is another important factor fuelling the market growth. Additionally, the key players in the market are focusing on strategies such as acquisition, partnerships, product development, and others.

In the U.S., one in 20 people is diagnosed with appendicitis. The condition is found to be rare under age 2 and most common between ages 10 and 30.
The global appendicitis market is expected to grow at a CAGR of 4.2% during the forecast period.
Segments                                                                                                                                            
The global appendicitis market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of type, the market is segmented into acute, and chronic appendicitis.
On the basis of diagnosis, the market is segmented into physical examination, White Blood Cell count, urinalysis, and imaging test.  Imaging Test is further segmented into abdominal X-ray, ultrasonography, CT scan, laparoscopy, and others
On the basis of treatment, the market is segmented antibiotics, appendectomy, and others.
On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Regional Analysis of the Global Appendicitis Market              
Considering the global scenario of the gall bladder treatment market, there are four main regions: America, Europe, Asia Pacific, and the Middle East & Africa.
America accounts for the largest market share owing to the rising prevalence of acute appendicitis. Presence of major medical device manufacturers and pharmaceutical companies, well-developed healthcare industry also determine the market growth. America consists of two regions namely, North America and South America. North America holds the major market share owing to the rising awareness about prevalence of appendicitis among children and adults, and availability of emergency diagnostic services. Additionally, increasing healthcare expenditure by the developed economies such as the U.S is another important factor for fuelling the growth of the market in Americas.
Europe holds the second largest market share in global appendicitis market. Germany, France and the U.K are the major contributors to the Europe appendicitis market owing to increasing demand for the technological advanced diagnostic devices, and overall growth of healthcare sector. Pharmaceutical companies are engaged in research and development activities for the development of new drugs for appendicitis, which further fuels the growth of the market.
Asia Pacific is the fastest growing market increasing geriatric population, and introduction of new & advanced diagnostic options such as CT scan, and rising demand for specialty healthcare services in regions such as India have fuelled the market growth. Additionally, mergers, acquisitions, partnership, and other strategic approaches by key players in the market also fuels the market.
The Middle East & Africa account for the lowest share in the global appendicitis owing to steady but positive growth of healthcare sector form last few years. In the Middle East, the United Arab Emirates, and Saudi Arabia have well known specialty care centers for the treatment for chronic diseases, which will further determine the progress of healthcare industry. Moreover, developed healthcare infrastructure, government support and increasing healthcare expenditure in the Middle Eastern countries fuels the market growth. In Africa, there is an increasing demand for primary care services including diagnostic services for chronic diseases.

Key Players in the Global Appendicitis Market
Some of the key players in this market are Siemens (U.S.), General Electric Company (U.S.), Toshiba Medical Systems Corporation (Japan), Koninklijke Philips N.V. (Japan), Johnson & Johnson Services Inc. (U.S.), Pfizer (U.S.), Shionogi & Co., Ltd. (Japan), and others.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Healthcare Fraud Detection Market 2018 Market Challenge, Driver, Trends & Forecast to 2023

Market Details:
The global healthcare fraud detection market is set to grow at nearly 30 percent CAGR during 2017 to 2023 (forecast period). Growth of the industry is attributed to medical scams, heavy returns on investments, and fraudulent pressures. Alongside these factors, exploitation of medical funds and more patients seeking medical insurance also steer the market.
As a whole, healthcare frauds involve drug frauds, medical insurance frauds, and medicine frauds. Health insurance frauds happen when people or firms defraud government medical programs or insurers. The process via which these frauds are committed differ from time to time and the swindlers manage to come up with new ways & means of executing their crimes.

Fraud damages are generally compensated for, through the adoption of ‘False Claims Act.’  As per an analysis by MRFR (Market Research Future Reports), rising demand for reduction in medical expenses across suppliers & hospitals should drive the need for healthcare fraud detection. With eHealth, mHealth, EHR, and other info-enriched devices, any kind of communication breach between patients and caregivers has decreased.
The said factor has led to the production of massive information, enabling customized therapies and fraud prevention. Normally, patients are apprehensive about the adoption of such fraud detection tools. But, with the amalgamation of human & artificial intelligence, healthcare approaches are further personalized. Hence; the need for healthcare analytics rises, boosting the revenues of healthcare fraud detection.
Industry - Fragmentation:
The healthcare fraud detection market is segmented on the basis of components, kinds, end-users, delivery models, and geographies. Services and software form the components. Predictive analytics, descriptive analytics, and prescriptive analytics constitute the kinds. Some of the end-users consist of employers, regulatory/public agencies, private insurance payers, and third party services.
The remaining comprise payment integrity, insurance claim reviews, and identity & case management. Various delivery models are on-demand and on-premise. Americas, Asia Pacific, Europe, and the Middle East & Africa are the different regional markets.
Sub-Segment Leaders:
By components, services captured the largest shares. With the advent of newer fraud detection software and demand for fraud analytics, services are reported to grow at the maximum CAGR in the forecast period. Among kinds, descriptive analytics produced the largest incomes.
Prescriptive, on the contrary, would grow at the maximum rate. Its growth will owe to it making sure that the synergistic incorporation of prescriptions & predictions is aptly carried out. The end-user, private insurance payers occupied the biggest shares and are coerced into spending on fraud analytics. Their shares arose from significant ‘cost-saving’ prospects and agreement with strict terms & conditions.
By delivery models, on-demand can grow at the maximum rate during 2017 to 2023. On-demand’s huge CAGR is ascribed to more adaptability, the need for self-driven analytics, and shortage of hardware funds. Americas, with regards to regions, led the worldwide healthcare fraud detection market.
This region was followed by Europe and propelled by technological developments, accessibility to products & services, and emphasis on pricing cut backs. While this industry opens novel prospects for many companies, its growth could be hampered by regular improvisations, time-consuming usage, and lack of proficient experts.

Prominent Market Companies and Innovations
SAS, Optum, IBM, Conduent, Pondera, and Wipro are some of the eminent players operating in the global market. CMS (Centers for Medicare and Medicaid Services), lately, optimized predictive modeling to detect fraud claims prior to them being paid. This cutting-edge technology is akin to what credit card firms adopt to detect fraudulent activities and distrustful conduct. It offers an active anti-fraud solution to the CMS. Some of the growth strategies employed by the above players are product launches and research & development initiatives.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Embolization Particle Market Volume Forecast and Value Chain Analysis 2018


Market Scenario

Embolization is a minimally invasive therapy to stop bleeding as well as to stop blood flow to a tumor in order to shrink it or in preparation for removal. In this procedure, some embolized particles or substances are injected into the veins of the patients to block or reduce the blood flow to cancer cells. Embolization is an option for some patients with tumors that cannot be removed by surgery. It can be used for tumors that are too large to be treated with ablation (usually larger than 5 cm thickness). It can also be used with ablation. Embolization does reduce some of the blood supply to the normal liver tissue, so it may not be a good option for some patients whose liver has been damaged by diseases such as hepatitis or cirrhosis. Embolization is used in many procedures as a part of interventional radiology.

The embolization particle market is expecting a healthy growth during the forecast period. With the growing use of embolization technique as a treatment for conditions other than cancer such as vascular malformations and fibrosis is fuelling the demand for embolization particles globally. Continuous introduction of technically advanced products with enhanced efficiency is also supporting the global market growth.
According to World Health Organization, an estimated 17.7 million people died from cardiovascular diseases in 2015, representing 31% of all global deaths
Total number of global volume of cardiovascular procedures is expected to increase on average by 3.7% per year to over 18.73 million corresponding to surgeries and transcatheter interventions in the year 2022
However, less number of interventional neuroradiologists and interventional neuroradiology (INR) labs and strict regulatory rules may hamper the market growth during the forecast period.
The global embolization particle market is expected to grow at a CAGR of 9.64% during the forecast period 2017-2023.
Segmentation                                                                                                                                      
The global embolization particle market is segmented on the basis of product type, application, level of occlusion and end user.
On the basis of the product type the embolization particle market is further segmented into radioembolization and drug eluting beads.
On the basis of applications, the market is segmented into oncology, urology, peripheral vascular disease, neurology, and others.
On the basis of level of occlusion the market is segmented into proximal and distal.
On the basis of end user, it is segmented into hospitals & clinics, ambulatory services and others.

Key Findings
  • The market for embolization particle is expected to reach around USD 1,909.76 million by 2023.
  • Radioembolization accounts the largest market share in 2016 and which is projected grow at a CAGR of 10.01% during the forecast period from 2017-2023.
  • Americas hold the largest share of the embolization particle market and is expected to reach USD 703.13 million by 2023.
  • Asia Pacific is the fastest growing region across the globe and expected to grow at a rate of CAGR 10.11% during the forecast period. 
Regional Analysis
The Americas dominate the global embolization particle market owing to the presence of strong economic condition, huge development in the healthcare domain, and focus of research institutions on updating technology for new and advanced diagnosis and treatment methods. Moreover, advanced hospitals infrastructures, and availability of skilled healthcare professional is further adding fuel to the growth of the market.  
Europe holds the second position in the market on the basis of increasing emphasis on rapid diagnosis and treatment of cancer, changing lifestyle, increasing prevalence of cancer among geriatric population. As per the Organization for Economic Co-operation and Development (OECD), Germany spent 11% of the total GDP on healthcare in 2013, which was 10.8% in 2012, which drives the growth of the market in this region. 
Asia Pacific is the fastest growing market owing to more number of developing nations present in this region, for instance, countries like India and China. These countries are encouraging the growth of the healthcare domain. Furthermore, increasing patient population from cancer in developing countries will directly increase the demand for various diagnosis & treatment methods, which, in turn, will boost the growth of the market.    
The Middle East & Africa is expected to hold the least market share due to less availability of medical facilities, and less development in the healthcare domain. However, countries such as Qatar and Kuwait are focusing more on the healthcare domain and developing medical facilities, which will boost the market of this region. 

Key Players                                                                                                         
Some of the key players in this market are Boston Scientific Corporation, Guerbet, BTG International Ltd, Medtronics, Sirtex, Terumo, and Merit Medical.


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Thyroid Disorder Market 2018 Global– Key Players, Size, Trends, Growth- Analysis To 2022


Market Synopsis of Global Thyroid Disorder Market
Market Scenario: 
Thyroid gland convert iodine taken from food into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism, growth and development, intelligence deficit etc. Thyroid hormones also affect fertility, kidney functions and cardiac functions as well. According to the international thyroid society almost 20 million Americans suffer from some form of thyroid disease and more than 12 percent of the U.S. population will develop a thyroid condition during their lifetime. The World Health Organization (WHO) has identified that iodine deficiency can easily be prevented which if not done can cause brain damage.
The market driving factors for world thyroid disorder market are growing screening and prevalence of thyroid disorders, good reimbursement for treatment and increasing awareness of implications of thyroid disorders.
Other factors driving the market’s growth are rise in risk factors such as obesity, diabetes, auto immune diseases etc. For example the percentage of the population diagnosed with hashimoto’s thyroiditis is growing and its occurrence is twice in patients who have diabetes. Increasing focus of developing regions’ governments on the healthcare sector is also driving the thyroid disorders treatment market. Rise in the number of thyroid cancer cases and the high cure rates of thyroid cancer is another factor driving the growth of this market.
The market’s restraints are the costs associated with the treatment and the rise of alternative medicines for the treatment of thyroid disorders. However, side-effects associated with the current medication is the most critical restraint. Thyroid disorders treatment medication have a low therapeutic index which is the difference between safe and effective dose.
The market for thyroid disorders is a consolidated market with few companies dominating the market. Among the hypothyroidism drugs Levothyroxine, Cytomel and Liothyronine top the market, while hyperthyroidism market leaders include imidazole and propacil.
Taking all the factors into consideration, we expect the global thyroid disorder market which was US$1990 million in 2016 to reach US$2400.8 million by 2022, growing with a CAGR of 3.1%.
Study Objectives Global Thyroid Disorder Market:
  • To provide detail analysis of the market structure along with forecast for the next 6 years of various segments and sub-segments of the global thyroid disorder market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.
  • To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries which includes Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future growth prospect.
  • To provide country level analysis of the market for segments which includes by treatment (drugs and supplements, diagnostics and surgery), by disease indication (hypothyroidism, hyperthyroidism and other), by route of administration (oral, injectable and others) and by end users (hospitals and home use)
  • To provide overview of key players and their strategic profiling in the market; comprehensively analyzing their core competencies and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments globally. 

Intended Audience
  • Thyroid diagnostic and surgical manufacturers
  • Anti-thyroid disorder drugs suppliers
  • Private research laboratories
  • Research and development (R&D) companies
  • Market research and consulting service providers
  • Government research laboratories
  • Contract manufacturing organizations 
Key Players for Global Thyroid Disorder Market:
Some of the key players in this market are namely Allergan, Abbott Laboratories, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., RLC LABS, AbbVie, Mylan and others.
Segments:
Global thyroid disorder market has been segmented on the basis of treatment which comprises of drugs and supplements, diagnostics and surgery. On the basis of disease indication; market is segmented into hypothyroidism, hyperthyroidism and other. On the basis of route of administration the market is segmented into oral, injectable and others. On the basis of end users the market is segmented into hospitals and home use.
Regional Analysis of Global Thyroid Disorder Market:
Globally America is the largest market for thyroid disorder and Europe is the second-largest market. Developed regions are expected to lose their market leadership in future due to growing Asia Pacific region which is expected to be the fastest growing region in thyroid disorder market. This region will be led by China and India. Africa is expected to be a moderately growing market in the global thyroid disorder market.
The report for global thyroid disorder market by Market Research Future comprises of extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the global thyroid market’s segments and regions.


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Wednesday, 9 May 2018

Atrial Fibrillation Market Dynamics, Forecast, Analysis and Supply Demand 2018


Industry Overview
The worldwide atrial fibrillation market is predicted to grow at a double digit CAGR over the forecast period (2017 to 2023). Atrial fibrillation, also denoted as AF, is an irregular or fast heart rhythm. It raises the dangers of chest pain, heart strokes, congestive heart failure, or cardiac discomfort. The typical indications of AF are dizziness, confusion, fainting, or tiredness.
AF cases within the elderly population, preference for catheter ablation, and escalating technological developments propel the AF market. Atrial fibrillation is a majorly common arrhythmia that results in disturbed cardiac rhythms. In the last twenty years, a higher existence of AF incidences has been witnessed around the globe. The ‘American Heart Association’ stated that about 34 million people were afflicted with AF globally in 2013.
Also, the United States observes approximately 200, 000 to 400, 000 fresh cases every year. Rising AF cases have been the key contributor of this industry. Moreover; diabetics, high-blood pressure patients, and obese people have developed cardiac problems, eventually propelling the industry. Rheumatic fever incidences have seen a rise, driving the atrial fibrillation market from 2017 to 2023.

Scientists and field experts have been collaborating to come up with innovative technologies for the premature diagnosis of AF. They have also been trying to offer better treatments to AF patients. Both these factors have generated higher demand for AF devices, furthering industry growth. On the other hand, increase in therapeutic expenses and scarcity of proficient doctors hamper the market.
According to a study by ‘Market Research Future’ (MRFR), the global AF market is set to experience decent expansion in the forecast period. Various lifestyle illnesses, poor eating habits, and sedentary occupations may also cause a surge in cardiac issues, leading to some of the AF incidences. All these factors could further contribute to the growth of this industry. Another hindrance for the market comprises the inclination towards pharmaceutical drugs over AF therapeutics.
Classification/Segmentation
The global atrial fibrillation market is divided on the basis of products, end-users, and geographical regions. By products, the industry is fragmented into non-surgical and surgical. The end users consist of cardio centers, big hospitals, and heart specialty care enterprises. Geographical regions into which the market is split, comprise Americas, Europe, Asia Pacific, and the Middle East and Africa.
Catheter ablation, a sub-segment of surgical products, is typically adopted for managing & treating cardiac arrhythmias. It is normally advised for the management of atrial fibrillation when patients can neither tolerate nor be given anti-coagulation drugs. Hence, catheter ablation occupied major shares in 2015. It is reported to be the most rapidly growing sub-segment in the near future.
Modern heart specialty and cardiac centers should witness the maximum adoption of AF devices. In view of geographies, Americas maintains supremacy over the market and would do the same in the forecast period. The usage of high-tech products & services and improved medical infrastructure is accountable for the same. Mexican sellers and government have spent heavy capital on the AF industry.
Asia Pacific will grow at the fastest pace & be driven by its huge patient base and population. Additionally, its need for atrial fibrillation devices can increase owing to better medical infrastructure and high Chinese & Indian healthcare costs.

Worldwide Rivals and Innovative Trends
Some of the well-established players operating in the global market are Biosense Webster, Carima, Agricore, Medtronic, and St. Jude Medical. They focus on new therapies for gaining wide recognition and edge over one another.
Catheter ablation has been further modified to suit patient-needs and offer cutting-edge therapies for AF patients. Majority of the patients across developed nations are treated with catheter pulmonary vein ablation. Such patients do not recover from medicines and have symptomatic AF.                             

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Anti-Venom Market to Observe Strong Development by 2018


Market Scenario
Anti-venom is made up of hyperimmune globulins and various other proteins extracted from the serum of various animals. In the process animals have been immunized with the venom of a snake, and then proteins are extracted from it. Anti-venom is currently the cornerstone of therapy for the victims of venomous snake bites and has reduced the mortality of this condition. It can be species-specific, regional, or polyvalent. For instance, anti-venom directed against coral snake venom is regenerated by immunizing horses with venom from the eastern coral snake i.e. Micrurus fulvius. The use of anti-venom is associated with various adverse reactions and so is given to only those victims who develop local, systemic, or laboratory evidence of envenoming. The use of epinephrine, corticosteroids, and antihistamines is also recommended before anti-venom administration as it helps to reduce the occurrence and severity of acute or delayed hypersensitivity reactions which may occur in 20 to 90% of cases.
According to the World Health Organization (WHO), snake antivenom immunoglobulins is the only specific treatment for envenoming by snakebites. It is also estimated that nearly 4.5 to 5.4 million people are bitten by snakes in a year, and around 1.8 to 2.7 million out of them develop clinical illness after a snakebite.
It is noted that the increasing cases of snake bites and increasing government funding for R&D are the key factors driving the anti-venom market.
Various other factors such as the increasing patient pool, unmet medical needs, increasing awareness about antivenoms, enhancing regulatory framework, and increasing government assistance are continuously contributing to the growth of the global anti-venom market.
It is estimated that the Anti-Venom market is expected to grow at a CAGR 6.5% during the forecast period of 2017–2023.
Intended Audience
  • Pharmaceutical Companies
  • Research and Development (R&D) Companies
  • Diagnostic Laboratories
  • Government Research Institutes
  • Academic Institutes and Universities
Segmentation
The global anti-venom market is segmented by type, type of species, mode of action, product type, and end-user.
On the basis of type, the global anti-venom market is classified as polyvalent heterologous antivenom, monovalent heterologous antivenom, homologous antivenom, and small molecule anti-toxins.
On the basis of type of species, the global anti-venom market is classified as snakes, scorpions, spiders, and others. The snake segment is further classified as common cobra, common krait, Russell viper, and others.
On the basis of mode of action, the global anti-venom market is classified as cytotoxic, neurotoxic, haemotoxic, cardiotoxic, myotoxic, and others.
On the basis of product type, the global anti-venom market is classified as snake anti-venom, scorpion anti-venom, spider anti-venom, and others.
On the basis of end-user, the global anti-venom market is segmented into hospitals, clinics, ambulatory surgical centers, and others.
Regional Analysis
The Americas dominates the anti-venom market owing to the increasing cases of snake bites, and scorpion bites and high healthcare expenditure.
Europe holds the second position in the anti-venom market. The financial support by the government towards research and development and improvement in reimbursement scenario are expected to drive the European anti-venom market. According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014 i.e. EUR 321 billion which is further followed by France with EUR 237 billion and United Kingdom with EUR 223 billion. In 2016, the R&D expenditure in the pharmaceutical industry was EUR 35000 million, suggested by the European Federation of Pharmaceutical Industries and Association.
Asia Pacific is the fastest growing anti-venom market owing to a huge patient pool and increasing advancements in pharmaceuticals. According to the Indian Brand Equity Foundation (IBEF), in 2016 the generics market of India stood at USD 26.1 billion. As per the statistics suggested by the World Health Organization (WHO), it has been estimated that around 2.8 million people are bitten by snakes, and nearly 46 900 people die from snakebite every year.
The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.
Key players
Some of the key players in the global anti-venom market are Allison Medical, Inc., Artsana S.p.a., B. Braun Melsungen AG, Becton, Dickinson and Company, Boston Scientific Corporation, Hamilton Company, Hill-Rom, Hu-Friedy Mfg. Co., LLC, Johnson & Johnson Services, Inc, Medline Industries, Inc., Medtronic plc, Novo Nordisk A/s, Owen Mumford, Ltd., Roboz Surgical Instrument, Smiths Medical, Stryker Corporation, Terumo Corporation, Thermo Fisher Scientific, UltiMed, Inc., Ypsomed Holding AG, and others.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com